鼻咽癌淋巴结分组:预后意义、N分期及筛选诱导化疗候选者的标志物
本研究基于1224例非转移性鼻咽癌患者的MRI,评估淋巴结分组(同一淋巴结区域内至少3枚连续淋巴结)的预后价值。淋巴结分组是总生存、无进展生存、无远处转移生存和无区域复发的独立预后因素,将其从N1上调至N2可提高N分期预测效能,且淋巴结分组患者接受诱导化疗与生存改善相关。
要点
- MRI上同一淋巴结区域内至少3枚连续淋巴结定义为淋巴结分组,是鼻咽癌独立预后因素。
- 淋巴结分组可从N1上调为N2,改良N分期预测无进展生存和无远处转移生存的C指数高于AJCC分期。
- 淋巴结分组患者接受诱导化疗与总生存、无进展生存和无远处转移生存改善相关。
核心结论
- 淋巴结分组是鼻咽癌患者显著的预后因素,可从N1上调为N2,并可作为识别可从诱导化疗中获益患者的标志物。
研究设计与样本
- 研究纳入1224例非转移性鼻咽癌患者,回顾MRI评估包括淋巴结分组在内的淋巴结变量,采用Kaplan-Meier法和多因素Cox回归分析变量与生存的关联,Harrell一致性指数(C指数)衡量预后模型效能,匹配对分析比较有无淋巴结分组患者的诱导化疗结局。
关键影像表现/征象
- MRI上同一淋巴结区域内至少3枚连续淋巴结定义为淋巴结分组。
诊断标准与关键数值
- 淋巴结分组对总生存的风险比及95%CI为3.86(2.09-7.12),高于N2期的3.54(1.89-6.70)。
- 将淋巴结分组患者从N1上调为N2后,改良N分期预测无进展生存的C指数为0.664,高于AJCC系统的0.658(p=0.022)。
- 改良N分期预测无远处转移生存的C指数为0.699,高于AJCC系统的0.690(p=0.005)。
- 匹配对分析显示,N1和N2期淋巴结分组患者接受诱导化疗与总生存改善相关(p=0.022)、无进展生存改善相关(p=0.007)、无远处转移生存改善相关(p=0.021)。
临床应用与阅片要点
- 阅片时需评估同一淋巴结区域内是否存在至少3枚连续淋巴结,以满足淋巴结分组定义。
- 淋巴结分组阳性患者可从N1上调为N2,改良N分期在预测无进展生存和无远处转移生存方面C指数高于AJCC分期。
- 淋巴结分组可作为识别可能从诱导化疗中获益患者的标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to evaluate the value of nodal grouping (NG), defined as the presence of at least three contiguous lymph nodes (LNs) within one LN region, in staging and management of patients with non-metastatic nasopharyngeal carcinoma (NPC).
METHODS: MR images were reviewed to evaluate LN variables, including NG. The Kaplan-Meier method and multivariate Cox regression models evaluated the association between the variables and survival. Harrell's concordance index (C-index) was used to measure the performance of prognostic models. The outcome of induction chemotherapy (IC) in patients with and without NG was compared using matched-pair analysis.
RESULTS: In 1224 patients enrolled, NG was found to be an independent prognostic factor for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and regional recurrence-free survival. The hazard ratio and 95% confidence interval (CI) of NG for OS (3.86, 2.09-7.12) were higher than those of stage N2 (3.54, 1.89-6.70). On upgrading patients with NG from stages N1 to N2, the revised N staging yielded a higher C-index compared to the American Joint Committee on Cancer system in predicting PFS (0.664 vs. 0.658, p = 0.022) and DMFS (0.699 vs. 0.690, p = 0.005). Results of the matched-pair analysis revealed that for patients with NG in stages N1 and N2, IC was correlated with improved OS (p = 0.022), PFS (p = 0.007), and DMFS (p = 0.021).
CONCLUSIONS: NG is a significant prognostic factor for patients with NPC. Patients with NG may be upgraded from stages N1 to N2. NG was also a marker for identifying patients who would benefit from IC.
KEY POINTS: • Nodal grouping, defined as the presence of at least three contiguous LNs within one LN region on MRI, was identified as a significant prognostic factor. • In patients with nasopharyngeal carcinoma, nodal grouping may influence lymph node staging. • Nodal grouping was a marker for identifying patients who may benefit from induction chemotherapy.
引用
- Liu Y, Chen S, Dong A, et al. Nodal grouping in nasopharyngeal carcinoma: prognostic significance, N classification, and a marker for the identification of candidates for induction chemotherapy. Eur Radiol. 2019. PMID: 31811429. doi:10.1007/s00330-019-06537-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。